April 25, 2022
To: All Concerned Parties
Company Name: Solasia Pharma K.K.
Representative: | Yoshihiro Arai, President & CEO |
(Code number: | 4597, TSE Growth Section) |
Contact: | Toshio Miyashita, CFO, Director |
Tel: | 81-3-5843-8046 |
URL: | https://solasia.co.jp/en/ |
Solasia's Partner, Isofol announced start of study data analysis of SP-05 (arfolitixorin) phase III AGENT study
Isofol Medical AB (publ) (STO: ISOFOL), Solasia's partner announced that the start of data analysis of the multi-center, global Phase III AGENT Study investigating arfolitixorin in combination with 5-FU, oxaliplatin and bevacizumab in advanced, metastatic colorectal cancer (mCRC).
For more information, please refer to the Isofol´s website.https://isofolmedical.com/
###
1
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Solasia Pharma KK published this content on 25 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 April 2022 23:58:09 UTC.